Optimizing resynchronization therapy: can we increase the number of true responders?
Cardiac resynchronization therapy is now considered a standard therapy for patients with cardiomyopathy, heart failure, and interventricular conduction delay. Despite the demonstrated benefits in multiple large-scale trials, there is a clear nonresponder rate. This brief review will address some of the issues associated with maximizing the benefit of biventricular pacing, and whether or not advances in programming of such devices will increase the number of true responders.